You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 10,143,747

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,143,747

Title:	Breast cancer therapeutics
Abstract:	The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.
Inventor(s):	Penninger; Josef (Vienna, AT), Schramek; Daniel (Vienna, AT)
Assignee:	IMBA--INSTITUT FUR MOLEKULARE BIOTECHNOLOGIE GMBH (Vienna, AT)
Application Number:	13/825,655
Patent Claims:	1. A method of delaying the onset of a primary breast or mammary cancer in a human patient comprising administering a therapeutically effective amount of anti-RANKL antibody to said patient; wherein the patient does not have cancer, wherein the patient is a pre-menopausal female at risk of developing the primary breast or mammary cancer, and wherein the patient does not show bone loss. 2. The method of claim 1, wherein the patient has received one or more treatments selected from treatment with a female sexual hormone, hormone replacement therapy and treatment with a hormone contraceptive. 3. The method of claim 1, wherein the anti-RANKL antibody is administered in combination with a therapy of female sexual hormones. 4. The method of claim 1, wherein the anti-RANKL antibody is administered in a pharmaceutical composition together with a hormone or derivative thereof selected from estrogen, progesterone, a progestin and a hormone contraceptive. 5. The method of claim 4, wherein the composition further comprises a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and/or adjuvant. 6. The method of claim 1, wherein the anti-RANKL antibody is administered together with a chemotherapeutic agent for prevention of breast or mammary cancer. 7. The method of claim 1, wherein the primary breast or mammary cancer does not overexpress HER2/neu. 8. The method of claim 1, wherein said anti-RANKL antibody is denosumab.

Details for Patent 10,143,747

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010	⤷ Try a Trial	2030-09-22
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010	⤷ Try a Trial	2030-09-22
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.